

1 **mRNA vaccine boosting enhances antibody responses against SARS-CoV-2**
2 **Omicron variant in patients with antibody deficiency syndromes**

3
4 Ofer Zimmerman*^{1,9}¶, Alexa Michelle Altman Doss^{2,9}, Paulina Kaplonek³, Laura A.
5 VanBlargan¹, Chieh-Yu Liang^{1,4}, Rita E. Chen^{1,4}, Jennifer Marie Monroy¹, H. James Wedner¹,
6 Anthony Kulczyk¹, Tarisa L. Mantia¹, Caitlin C. O'Shaughnessy¹, Hannah G. Davis-Adams¹,
7 Harry L. Bertera³, Lucas J. Adams⁴, Saravanan Raju⁴, Fang R. Zhao¹, Christopher J. Rigell¹,
8 Tiffany Biason Dy¹, Andrew L. Kau^{1,5}, Zhen Ren¹, Jackson Turner⁴, Jane A. O'Halloran¹,
9 Rachel M. Presti^{1, 7}, Daved H. Fremont⁴, Peggy L. Kendall^{1,4}, Ali H. Ellebedy^{4,6,7}, Galit Alter³,
10 and Michael S. Diamond*^{1,4,6,7}

11
12 ¹ Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA

13 ² Department of Pediatrics, Washington University in St. Louis, St. Louis, MO 63110, USA

14 ³ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

15 ⁴ Department of Pathology and Immunology, Washington University School of Medicine, St.
16 Louis, MO 63110, USA

17 ⁵ Center for Women's Infectious Disease Research, Washington University School of Medicine,
18 St. Louis, MO 63110, USA

19 ⁶ Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
20 MO 63110, USA.

21 ⁷ The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy
22 Programs, Washington University School of Medicine, St. Louis, MO 63110, USA

23
24 ⁹ These authors contributed equally to this manuscript.

25 * Corresponding authors: Michael S. Diamond mdiamond@wustl.edu and Ofer Zimmerman,
26 zimmero@wustl.edu

27 ¶ Lead Contact: Ofer Zimmerman, zimmero@wustl.edu

28

29

30 **ABSTRACT**

31 Patients with primary antibody deficiency syndromes (PAD) have poor humoral immune
32 responses requiring immunoglobulin replacement therapy. We followed PAD patients after
33 SARS-CoV-2 vaccination by evaluating their immunoglobulin replacement products and serum
34 for anti-spike binding, FcγR binding, and neutralizing activities. Immunoglobulin replacement
35 products had low anti-spike and receptor binding domain (RBD) titers and neutralizing activity.
36 In COVID-19-naïve PAD patients, anti-spike and RBD titers increased after mRNA vaccination
37 but decreased to pre-immunization levels by 90 days. Patients vaccinated after SARS-CoV-2
38 infection developed higher responses comparable to healthy donors. Most vaccinated PAD
39 patients had serum neutralizing antibody titers above an estimated correlate of protection against
40 ancestral SARS-CoV-2 and Delta virus but not against Omicron virus, although this was
41 improved by boosting. Thus, currently used immunoglobulin replacement products likely have
42 limited protective activity, and immunization and boosting of PAD patients with mRNA
43 vaccines should confer at least short-term immunity against SARS-CoV-2 variants, including
44 Omicron.

45
46 **KEYWORDS:** SARS-CoV-2; COVID-19; combined variable antibody deficiency; specific
47 antibody deficiency; hypogammaglobulinemia, vaccine, mRNA vaccine, neutralization, immune
48 response

49

50 INTRODUCTION

51 Common variable immune deficiency (CVID) and other primary antibody deficiency
52 syndromes (PAD) are associated with low immunoglobulin levels and impaired antibody
53 responses to pathogens and vaccines^{1,2}. Patients with these immune disorders suffer from severe
54 and recurrent infections, autoimmunity, and are at increased risk for malignancies³. CVID has a
55 prevalence of 1 to 25,000⁴⁻⁶ and is the most common primary immunodeficiency in patient
56 registries with more than 20% suffering from this condition. CVID is not a single disease but
57 rather a collection of hypogammaglobulinemia syndromes resulting from multiple genetic
58 defects⁷⁻¹¹. Most patients with PAD require intravenous or subcutaneous immunoglobulin
59 replacement therapy that decreases their risk for infection¹²⁻¹⁴. There are more than 15
60 commercially available immunoglobulin products in the United States. The production of
61 immunoglobulin replacement products takes up to one year from sample donation to
62 distribution^{15,16}. Each vial contains immunoglobulins pooled from thousands of donors^{16,17}, and
63 each manufacturer has its own plasma donors. In patients with PAD, immunoglobulin
64 replacement is dosed every 1 to 4 weeks, depending on the route of administration.

65 SARS-CoV-2 is the causative agent of the global COVID-19 pandemic. From November
66 2019 until now, the virus has caused at least 5.5 million deaths. In the United States, the
67 emergency use authorization has been granted for two COVID-19 vaccines (mRNA-1273,
68 Moderna and Ad26.COV2.S, Johnson & Johnson/Janssen) and full approval has been given to
69 one mRNA vaccine (BNT162b2, Pfizer-BioNTech). Presently, there is limited data regarding the
70 effectiveness of mRNA or adenoviral vector vaccination against COVID-19 in CVID or PAD
71 patients. Several studies showed variable seroconversion rates with detection of anti-spike, S1 or
72 RBD antibodies, in 20 to 90% of PAD patients following vaccination with BNT162b2, mRNA-

73 1273, or ChAdOx1 (Oxford-AstraZeneca)¹⁸⁻²¹, with better responses in those with prior history
74 of SARS-CoV-2 infection^{20,22}. Available data are limited to the initial vaccine response with no
75 information on durability or the effect of boosting in PAD patients. Furthermore, no data has
76 been published on the ability of PAD patient serum to neutralize authentic SARS-CoV-2 and
77 variants, including the currently dominant B.1.1.529 (Omicron) virus. Finally, no study has
78 reported the anti-spike, anti-RBD, or neutralization activity of immunoglobulin replacement
79 products that PAD patients had received, to rule out the possibility that their anti-SARS-CoV-2
80 antibodies originated from passive immunoglobulin therapy. To address these gaps, we evaluated
81 the effect of mRNA vaccination and boosting on serum antibody responses in PAD patients
82 against historical SARS-CoV-2 strains and key circulating variants.

83

84 RESULTS

85 **Antibody binding to spike and RBD.** To begin to determine the baseline immunity
86 afforded by antibody replacement therapy for our patient cohort, we tested 48 distinct lots of 6
87 different immunoglobulin products (**Table S1**) for binding to historical (Wuhan-1) spike and
88 RBD proteins and compared these results to serum from 12 healthy donors (HD) before or 14
89 and 90 days post-completion of 2 doses of BNT162b2 mRNA vaccine (**Fig 1A-B**). Only one
90 immunoglobulin product, Gamunex-C, showed anti-spike antibody titers higher than
91 unvaccinated HD, and these values were substantially lower than those from HD 14 and 90 days
92 post-immunization ($P < 0.001$) (**Fig 1A**). In all tested immunoglobulin products, anti-RBD titers
93 were not different from those of unvaccinated HD (**Fig 1B**). Thus, antibody replacement
94 products in clinical use at the time of this study (May 2021-January 2022) had remarkably low
95 levels of anti-SARS-CoV-2 antibody and likely were derived from donations obtained before or
96 soon after the onset of the pandemic.

97 We next compared anti-spike and anti-RBD titers of 27 PAD patients (**Table 1 and S2-**
98 **S3**) who completed immunization with mRNA vaccines (BNT162b2, $n = 19$, mRNA-1273, $n =$
99 8) to those of 20 HD immunized with BNT162b2. Nineteen patients had COVID, with the others
100 having hypogammaglobulinemia ($n = 4$) or specific antibody deficiency ($n = 4$) diagnoses. Nine
101 of the 27 PAD patients had a confirmed history of prior COVID-19 infection by RT-PCR and
102 were convalescent or recovered (COVID-19-experienced, range of 36-276 days from infection to
103 vaccination; median 106 days; mean 130 days). Because of the study design, we obtained pre-
104 vaccination serum samples from only a subset (9 of 30) of individuals in the PAD cohort.
105 Notwithstanding this limitation, our analysis of immunoglobulin replacement samples (**Fig 1A-**
106 **B**) suggests that individuals without a prior history of SARS-CoV-2 infection should have low, if

107 any, levels of pre-existing anti-spike or RBD antibody. Fourteen days post-immunization, both
108 COVID-19-naive and -experienced PAD patients as well as HD had anti-spike titers that were
109 higher than the pre-vaccination anti-spike titers (59-fold, COVID-19-naive PAD; 53-fold,
110 COVID-19-experienced PAD; and 55-fold, HD) (**Fig 1C**). However, at 90 days post-vaccination,
111 PAD patients without a history of SARS-CoV-2 infection showed waning anti-spike titers to
112 levels that were not higher than pre-vaccination baselines (**Fig 1C**). In contrast, anti-spike titers
113 from COVID-19-experienced PAD and HD remained higher than pre-vaccination levels (17-
114 fold, COVID-19-experienced PAD; 41-fold, HD) (**Fig 1C**). Similar findings were observed with
115 anti-RBD titers. Fourteen days post-immunization, all groups had higher anti-RBD titers than the
116 pre-vaccination (19-fold, COVID-19-naive PAD; 19-fold, COVID-19-experienced PAD; and 39-
117 fold, HD) (**Fig 1D**). At 90 days post-vaccination, anti-RBD titers of COVID-19-naive PAD
118 patients were not higher than baseline (**Fig 1D**), whereas titers of COVID-19-experienced PAD
119 and HD had decreased but remained higher than before immunization (4-fold, COVID-19-
120 experienced PAD; 17-fold, HD) (**Fig 1D**). Thus, vaccinated HD and COVID-19-experienced
121 PAD patients had higher anti-spike and anti-RBD responses than vaccinated PAD patients
122 lacking a history of SARS-CoV-2 infection (**Fig 1C-D**).

123 Seventeen PAD patients received a booster dose with an mRNA vaccine (range of 65-185
124 days from initial vaccine completion to booster; median 141 days; mean 135 days) (**Table 1**),
125 and samples were obtained one to four weeks later (n = 16, range 7-27 days, median 17 days,
126 mean 17 days; one patient had a post-booster sample drawn at day 35). Serum anti-spike and
127 RBD titers were higher after boosting than those obtained pre-booster (5 to 9-fold compared to
128 day 90, and 19 to 32-fold compared to day 150; **Fig 1E-F**). Although the anti-spike and RBD
129 titers after boosting trended higher than those obtained at 14 days post primary immunization,

130 these differences did not reach statistical significance ($P > 0.3$). Moreover, 90 days after
131 boosting, serum titers against spike and RBD from PAD patients had decreased to levels
132 comparable to before boosting (**Fig 1E-F**).

133 **Immunoglobulin subclass and Fc-gamma receptor binding.** Recent studies have
134 suggested that immunoglobulin subclass and antibody interactions with Fc γ receptors (Fc γ R) can
135 contribute to protective immunity against SARS-CoV-2^{23,24}. Accordingly, we evaluated serum
136 from immunized PAD patients for their immunoglobulin subclasses (IgG1, IgG2, IgG3 and
137 IgG4, IgA, and IgM) that bind spike proteins and domains (S, S1, S2, and RBD) from historical
138 (Wuhan-1) and spike proteins from B.1.351 (Beta) and B.1.617.2 (Delta) SARS-CoV-2 strains
139 (**Fig 2A-F; Fig S1**). Fourteen days after primary series immunization, COVID-19-naive PAD
140 had lower IgG2, IgG3, and IgM levels against spike and RBD proteins of all 3 tested virus
141 strains than vaccinated HD (**Fig 2B-C and F**). COVID-19-naive PAD patients also had lower
142 IgG1 levels against Wuhan-1 SARS-CoV-2 spike and RBD than HD (**Fig 2A**). In comparison,
143 vaccinated COVID-19-naive PAD patients had IgA titers against spike and RBD proteins that
144 were similar to HD (**Fig 2E**). Vaccinated COVID-19-experienced PAD patients had lower IgG3
145 levels against Wuhan-1 spike, S1, and RBD (**Fig 2C**), but similar levels of IgG1, IgG2, IgA, and
146 IgM against Wuhan-1 spike, S1, S2, and RBD and variant spike proteins compared to
147 immunized HD (**Fig 2A-B and E-F**). Vaccinated, COVID-19-experienced PAD patients had
148 higher levels of IgG2, IgA, and IgM against Wuhan-1 spike and RBD than vaccinated, COVID-
149 19-naive PAD patients. COVID-19-experienced PAD patients had higher IgG3, IgA and IgM
150 titers against S2 protein than COVID-19-naive PAD patients (**Fig 2C, E-F**). The levels of IgG4
151 anti-spike or RBD protein in all groups were near the limit of detection (**Fig 2D**). Although prior
152 infection with COVID-19 in PAD patients was associated with a better vaccine response,

153 COVID-19-naive and -experienced PAD patients had lower IgG3 responses than HD (**Fig 2C**
154 **and S1**). This result suggests that class switching to IgG3 is impaired in PAD patients following
155 infection or vaccination.

156 Given these results, we next evaluated anti-spike and anti-RBD antibody binding to
157 FcγRs (FcγR2A, FcγR2B, FcγR3A and FcγR3B) using a systems serology platform²⁵.
158 Vaccinated, COVID-19-naive PAD patients had lower levels of FcγR binding to anti-spike and
159 RBD antibody than vaccinated, COVID-19-experienced PAD patients or HD (**Fig 2G-J**).
160 FcγR2A, 3A and 3B binding was higher in serum from vaccinated, COVID-19-experienced PAD
161 patients than vaccinated, COVID-19-naive PAD patients for all viral antigens tested (**Fig 2G, I-J**
162 **and S1**). COVID-19-experienced PAD patient serum binding to FcγR2B was higher than
163 COVID-19-naive PAD patients for Wuhan-1 and B.1.617.2 spike proteins (**Fig 2H**). FcγR2A,
164 FcγR2B, FcγR3A and FcγR3B binding was higher in HD than COVID-19-naive PAD patients
165 for most spike proteins (**Fig 2G-J and S1**). Serum anti-S2 responses from COVID-19-
166 experienced PAD patients were higher than COVID-19 PAD patients for all tested FcγRs (**Fig**
167 **2G-J**). The higher levels of FcγR binding by anti-spike and anti-RBD antibodies in COVID-19-
168 experienced compared to COVID-19-naive PAD patients after vaccination suggest that PAD
169 patients do not have an inherent defect in producing antibodies that mediate Fc effector
170 functions.

171 **Serum neutralizing antibody responses.** We evaluated the functional activity of
172 antibody preparations by performing focus reduction neutralization tests (FRNTs) with authentic
173 SARS-CoV-2 strains and variants (WA1/2020, B.1.617.2, and B.1.1.529). We first tested
174 neutralizing activity of the commercial immunoglobulin products (n = 17), serum from COVID-
175 19-naive PAD patients after vaccination (n = 18), and serum from COVID-19-experienced

176 patients after vaccination (n = 9) (**Fig 3A-B**). Fourteen of 17 different lots of immunoglobulin
177 product tested had no appreciable neutralizing activity against WA1/2020 or B.1.617.2 at 500
178 $\mu\text{g/ml}$ (**Fig 3A-B and S2**), which is approximately a 1/50 dilution of the mean IgG concentration
179 measured in our PAD patients on IgG replacement therapy (9.7 mg/ml) (**Table S1 and S2**). We
180 tested this concentration (rather than neat sample) since it corresponds to the serum dilution that
181 is the presumed cutoff for vaccine-mediated protection²⁶. Two lots of Gammunex-C and one of
182 Hizentra had limited neutralizing activity against WA1/2020 strain at a 1/50 dilution, and only
183 one lot (Hizentra) had inhibitory activity against B.1.617.2 at this dilution (**Fig 3A-B; S1-S2,**
184 **Table S1**).

185 As expected, serum of COVID-19-naive PAD patients had no neutralizing activity
186 against WA1/2020 prior to vaccination, whereas COVID-19-experienced patients did (**Fig**
187 **3A**). Fourteen days after immunization, 15 of 18 (83%) COVID-19-naive PAD patients had
188 levels of serum neutralizing antibodies against WA1/2020 that are considered protective²⁶ (titer >
189 50). By 90 days, neutralizing activity had waned, with 12 of 17 (71%) PAD patients in this group
190 still having titers above the presumed protective threshold. Following boosting, neutralizing
191 titers increased in 11 of 12 (92%) COVID-19-naive PAD to levels greater than 50 against
192 WA1/2020 (**Fig 3A**). In the cohort of COVID-19-experienced PAD patients, serum neutralizing
193 activity against WA1/2020 exceeded the protective cutoff at all tested time points in all subjects
194 (**Fig 3A**). Indeed, 14 and 90 days post-primary immunization series, COVID-19-experienced
195 PAD patients had serum neutralizing titers against WA1/2020 that were 20 and 8-fold higher
196 than COVID-19-naive PAD patients, respectively (**Fig 3A**).

197 We repeated FRNTs with PAD patient serum and the B.1.617.2 Delta strain, which can
198 evade neutralizing antibodies due to amino acid substitutions in the RBD²⁷. Although pre-

199 immunization serum of COVID-19-naive patients lacked inhibitory activity against B.1.617.2,
200 serum from 4 of 5 (80%) COVID-19-experienced PAD patients neutralized B.1.617.2 before
201 vaccination (**Fig 3B**). Fourteen and 90 days post-vaccination 14 of 18 (78%) and 11 of 17 (65%)
202 COVID-19-naive patients, respectively had serum neutralizing titers against B.1.617.2 that were
203 above 50. Following boosting, 10 of 12 (83%) COVID-19-naive PAD patients had neutralizing
204 titers above 50 (**Fig 3B**). In comparison, 8 of 9 (88%), 6 of 6 (100%), and 3 of 3 (100%) of
205 COVID-19-experienced PAD patients had serum neutralizing titers against B.1.617.2 above the
206 presumed protective threshold at 14 and 90 days post-vaccination and 14 days post-boosting,
207 respectively. At 14 days post-vaccination, COVID-19-experienced PAD patients had 10-fold
208 higher serum neutralizing titers against B.1.671.2 than COVID-naive vaccinated patients (**Fig**
209 **3B**).

210 We next analyzed PAD patients (n = 17) who received an mRNA vaccine booster (**Fig**
211 **3C**). We included in this analysis two patients who initially received an Ad26.COV2.S vaccine
212 (**Table 1 and Fig S3**). At 14 days and 90 post-primary vaccination, 14 of 17 (82%) and 11 of 16
213 (69%) patients had serum neutralization titers above 50 against WA1/2020. At 14 days post-
214 boosting, 16 of 17 (94%) patients had neutralizing titers against WA1/2020 that exceeded 50
215 (**Fig 3C**), and the highest titers (GMT: 786) showed a 7-fold increase over levels at 90 days post-
216 primary series (**Fig 3C**). Ninety days post-boosting, 10 of 11 (91%) patients had neutralization
217 titers above 50 (**Fig 3C**). Similar findings were observed against B.1.617.2, with 12 of 17 (71%),
218 10 of 16 (63%), 15 of 17 (88%) and 8 of 11 (73%) PAD patients having neutralizing titers
219 greater than 50, at 14 and 90 days post-primary immunization series or at 14 and 90 days post-
220 boosting, respectively (**Fig 3D**). Similar to WA1/2020, the highest neutralization titers against
221 B.1.617.2 were detected 14 days after boosting (**Fig 3D**).

222 The B.1.1.529 Omicron variant has >30 substitutions, deletions, and insertions in its
223 spike protein, which jeopardizes the efficacy of vaccines designed against historical SARS-CoV-
224 2 strains²⁸⁻³⁰. Accordingly, we evaluated serum neutralizing activity against B.1.1.529 in our
225 patient cohort (**Fig 3E-F**). Fourteen days after completing the primary vaccination series, only 8
226 of 27 (30%) PAD patients had serum levels of neutralizing antibody above 50 against B.1.1.529
227 (**Fig 3E**), and only 1 of 8 patients in this group was COVID-19-naive. Fourteen days following
228 boosting, 12 of 17 (71%) PAD patients had neutralizing titers against B.1.1.529 that exceeded 50
229 (**Fig 3F**). Ninety days post-boosting, 5 of 11 (45%) PAD patients had serum neutralization titers
230 against B.1.1.529 that exceeded 50 (**Fig 3G**). The mean neutralization titer against B.1.1.529 was
231 lower than against WA1/2020 and B.1.617.2 at 14 days after primary immunization (~10-fold, P
232 < 0.0001), 14 days post-boosting (~4 to 8-fold, P < 0.05), and 90 days post-boosting (~6-fold, P
233 < 0.05), which is consistent with recent studies in immunized healthy cohorts²⁸⁻³⁰.
234

235 **DISCUSSION**

236 Our findings highlight the importance of immunizing and boosting PAD patients with
237 SARS-CoV-2 mRNA vaccines. Even though these patients have defects in their humoral
238 responses, vaccination is an important prevention option for PAD patients against COVID-19,
239 since immunoglobulin replacement products in use at the time of this study had limited
240 inhibitory activity, and several of the commercially available monoclonal antibody therapeutics
241 lose substantial neutralizing capacity against variants including B.1.1.529³¹⁻³³. Although two
242 doses of mRNA vaccines induce serum neutralizing antibodies in most PAD patients that
243 presumably would protect against historical and B.1.617.2 variant, PAD patients without a
244 history of SARS-CoV-2 infection had little to no serum neutralizing activity against B.1.1.529
245 (Omicron) following completion of a primary vaccination series. However, an mRNA vaccine
246 booster in PAD patients increased anti-B.1.1.529 responses in most individuals, although the
247 serum levels of neutralizing antibodies waned over time. Our findings support recent Center for
248 Disease Control and Prevention recommendations for a three-dose primary mRNA vaccine series
249 that also includes a booster dose 5 months later in moderately or severely immune suppressed
250 individuals³⁴.

251 In patients with no prior history of COVID-19 infection, the immune response to two
252 doses of mRNA vaccine was lower in magnitude and less durable than in HD or PAD patients
253 with a history of infection. Of note, the increase in serum neutralizing titers following boosting
254 was higher than the increase in anti-spike and anti-RBD titers (4.5-fold compared to 2-fold). This
255 observation highlights the utility of performing antibody neutralization assays in addition to
256 spike or RBD binding assays for assessing the quality of humoral immune responses. Although
257 further studies that sample and sequence B cells in blood from PAD patients are needed, we

258 speculate that B cells from at least some PAD patients undergo antibody maturation after
259 infection, vaccination, and boosting.

260 One limitation of our study is the heterogeneity in the PAD patient cohort, which
261 included those with CVID, hypogammaglobulinemia, or specific antibody deficiency. Although
262 this was a limitation of the cohort available for study, we did not observe substantive differences
263 between the patient subgroups. Instead, the most significant differences in antibody response to
264 mRNA vaccines were between patients that had or lacked a prior history of SARS-CoV-2
265 infection.

266 Many of our PAD patients who historically had poor immune responses to bacterial and
267 other protein antigens (*e.g.*, *Streptococcus pneumoniae* polysaccharides, tetanus toxoid, and
268 diphtheria toxin) as part of their initial immune workup (**Table S3**) responded to mRNA
269 vaccines. The basis for this difference remains unclear, although it could be due to the unique
270 adjuvant properties of the lipid nanoparticle or *in vitro*-synthesized mRNA³⁵⁻³⁷. In comparison,
271 although numbers in our cohort were clearly small ($n = 3$), we detected little to no antibody
272 response at 35, 60 or 90 days after immunization of COVID-naive PAD patients with the
273 Ad26.COV2.S adenoviral-vectored vaccine (**Fig S3**). Because PAD is a heterogeneous clinical
274 entity, with many of the genetic defects unknown⁷⁻¹¹, certain classes of adjuvants or antigens
275 may overcome specific deficiencies and promote B cell responses, albeit at lower levels than
276 healthy counterparts. Our data suggest that the mRNA platform may have utility for vaccination
277 of PAD patients. That said, their less durable response, lower level of anti-spike and anti-RBD
278 IgG3, and lower levels of complement-fixing and Fc γ R-engaging antibodies, suggest that more
279 frequent boosters may be required to establish and maintain protective immunity.

280 Our study also showed that many of the immunoglobulin replacement products currently
281 used have low levels of inhibitory anti-SARS-CoV-2 antibodies. This may be due to the long
282 lead time required for collection from donors, purification, and testing. Neutralization assays
283 performed by one manufacturer and by us showed low inhibitory activity against Wuhan-1 and
284 less activity against SARS-CoV-2 variants³⁸. The three products we identified with some activity
285 against Wuhan-1 and B.1.617.2 had titers that likely would not confer protection against
286 B.1.1.529 given the more extensive antibody evasion by this strain^{31,32,39,40}. Indeed, neutralizing
287 titers were below the presumed protective cutoff in the 4 COVID-19-naive PAD patients who
288 donated pre-vaccination blood samples, even though all had received immunoglobulin
289 replacement every 3 to 4 weeks before study enrollment. It is unclear when commercially
290 available products will have sufficient levels of specific and neutralizing anti-SARS-CoV-2
291 antibodies to protect PAD patients. Further binding and neutralization studies are warranted
292 once anti-SARS-CoV-2 antibodies become more widespread in plasma pools. While many PAD
293 patients might be eligible for long-acting combination monoclonal antibody prophylaxis (*e.g.*,
294 Evusheld [AZD7442]) against COVID-19, recent studies showed substantial (~33-fold) losses in
295 potency against B.1.1.529 Omicron virus. Thus, for now, immunization of PAD patients with
296 mRNA vaccines that includes a booster may be the most effective way to induce a protective
297 antibody response against SARS-CoV-2 and its variants.

298

299

300 **Acknowledgments**

301 This study was supported by grants and contracts from NIH: R01 AI157155, U01
302 AI151810, and 75N93019C00051 [all to M.S.D.], U01AI141990, U01AI150747,
303 HHSN272201400006C, HHSN272201400008C, and 75N93019C00051 [all to A.H.E.], and R01
304 DK084242 [to P.L.K.]. The study also was supported by a VA Merit Award (BX002882 [to
305 P.L.K.]). This study utilized samples obtained from the Washington University School of
306 Medicine COVID-19 biorepository, which is supported by the NIH/National Center for
307 Advancing Translational Sciences (UL1 TR002345). The WU353 and WU368 studies were
308 reviewed and approved by the Washington University Institutional Review Board (approval no.
309 202003186 and 202012081, respectively). The authors also express their gratitude to all study
310 participants.

311

312 **Author Contributions**

313 O.Z. designed the study, wrote the study protocol, performed experiments, analyzed the
314 data, and supervised the project. A.L.T.D. enrolled subjects, collected demographic and clinical
315 data, performed experiments, and analyzed data. L.A.V, C.L. and R.E.C designed and performed
316 FNRT experiments and analyzed data. P.K and H.L.B designed and performed Luminex
317 profiling. P.K analyzed Luminex data. J.M.M and C.J.R collected demographic and clinical data,
318 enrolled patients, and provided patient care. H.J.W, And.K., T.B.D, Ant.K. and Z.R. provided
319 patient care. T.L.M wrote the study protocol, managed IRB compliance, enrolled patients, and
320 processed patient samples. C.C.O collected patient demographic and clinical data, enrolled
321 patients, and processed samples. H.G.D performed SARS- ELISA CoV-2 spike and RBD protein
322 expression experiments. L.J.A and D.H.F generated crucial reagents. S.R. planned experiments

323 and analyzed data. F.Z. designed the study and analyzed data. A.H.E and J.T contributed samples
324 from the healthy donor cohort. J.A.O and R.M.P wrote and maintained the Institutional Review
325 Board protocol, recruited and phlebotomized participants and coordinated sample collection of
326 healthy donors. P.L.K supervised the project. GA designed experiments and analyzed data.
327 M.S.D planned experiments and analyzed data. O.Z. and M.S.D. wrote the initial draft, with all
328 other authors providing editorial comments.

329

330 **Competing Interests Statement**

331 M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, and Carnival
332 Corporation, and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond
333 laboratory has received unrelated funding support in sponsored research agreements from
334 Moderna, Vir Biotechnology, and Emergent BioSolutions. O.Z. and family own Moderna stock.
335 G.A. is a founder and equity holder for Seromyx Systems Inc., and an equity holder for Leyden
336 Labs. The Ellebody laboratory received unrelated funding support from Emergent BioSolutions
337 and AbbVie. A.H.E. is a consultant for Mubadala Investment Company and the founder of
338 ImmuneBio Consulting. J.S.T. is a consultant for Gerson Lehrman Group. J.S.T. and A.H.E. are
339 recipients of a licensing agreement with Abbvie that is unrelated to this manuscript.

340

341

342

343 **FIGURE LEGENDS**

344 **Figure 1. Anti-spike and anti-RBD titers following primary vaccination and**
345 **boosting in PAD patients.** Anti-Wuhan-1 Spike (**A**) and RBD (**B**) endpoint titers in 48 lots of 6
346 different immunoglobulin replacement products (squares) compared to 12 HD (blue circles)
347 before, 14 days and 90 days post-completion of BNT162b2 vaccine series. Anti-Wuhan-1 spike
348 (**C**) and RBD (**D**) endpoint titers in HD (n = 20; blue circles), COVID-19-naive (n = 18; red
349 circles) and COVID-19-experienced (n = 9; green circles) PAD patients before, or 14 and 90
350 days post-completion of mRNA (BNT162b2, n = 19 or mRNA-1273, n = 8) vaccination series.
351 Anti-Wuhan-1 Spike (**E**) and RBD (**F**) endpoint titers in COVID-19-naive (n = 14; red circles)
352 and COVID-19-experienced (n = 3; green circles) PAD patients before (n = 4), 14 or 28 (n = 17),
353 90 (n = 16) and 150 (n = 10) days post-completion of primary mRNA (BNT162b2 n = 13,
354 mRNA-1273 n = 2) or Ad26.COV2.S (n = 2) vaccine series, and 14 (n = 17) days and 90 (n =
355 10) days post-booster with mRNA vaccine (BNT162b2 n = 15; or mRNA-1273 n = 2). Dotted
356 black line represents the limit of detection. Numbers above graphed data (**E-F**) represent the
357 geometric mean titer (GMT) for each time point. One-way ANOVA with Dunnett's post-test;
358 Bars indicate mean values; Only significant differences are shown: *, $P < 0.05$; **, $P < 0.01$;
359 ***, $P < 0.001$; ****, $P < 0.0001$.

360 **Figure 2. IgG subclasses and FcγR binding activity of anti-spike antibodies in serum**
361 **from vaccinated PAD patients.** Levels of IgG1(**A**), IgG2 (**B**), IgG3 (**C**), IgG4 (**D**), IgA (**E**),
362 IgM (**F**), FcγR2A-binding (**G**), FcγR2B-binding (**H**), FcγR3A-binding (**I**), and FcγR3B-binding
363 (**J**) anti-Wuhan-1 (S, S1, S2, and RBD), anti-B.1.351, and anti-B.1.617.2 spike antibodies in HD
364 (n = 20, blue circles), COVID-19-naive (n = 18, red circles) and COVID-19-experienced (n = 9,
365 green circles) PAD patients 14 days following the completion of mRNA vaccine series. Two-

366 way ANOVA with Tukey post-test; mean; Only significant differences are shown: *, $P < 0.05$;
367 **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$).

368 **Figure 3. Neutralizing antibody responses in PAD patients following vaccination**
369 **and boosting.** Serum neutralizing activity against WA1/2020 (A) or B.1.617.2 (Delta) (B) in
370 COVID-19-naive (red circles) and COVID-19-experienced (green circles) PAD patients before
371 (n = 4 COVID-19-naive; n = 5, COVID-19-experienced), and 14 (n = 18, COVID-19-naive; n =
372 9, COVID-19-experienced) or 90 (n = 17, COVID-19-naive; n = 6, COVID-19-experienced)
373 days following mRNA vaccination and 14 days post mRNA booster (n = 12, COVID-19-naive; n
374 = 3, COVID-19-experienced). Neutralizing activity of immunoglobulin (Ig) replacement
375 products (n = 17, purple squares). Effect of boosting on serum neutralization of WA1/2020 (C)
376 and B.1.617.2 (D) in COVID-naive (n = 14, red circles) and COVID-19-experienced (n = 3,
377 green circles) PAD patients following completion of primary mRNA (14 or 90 days post-
378 vaccination; BNT162b2, n = 13; mRNA-1273, n = 2) or Ad26.COV2.S (28 or 90 days post-
379 vaccination; n = 2) vaccine series and 14 or 90 days post-boosting with mRNA vaccine
380 (BNT162b2, n = 15; or mRNA-1273, n = 2). Effect of variant strains on serum neutralizing
381 activity of PAD patients 14 days post completion of mRNA vaccination (E) (n = 27 total; n = 18,
382 COVID-19-naive, red circles; n = 9, COVID-19-experienced, green circles), 14 days post-
383 boosting (F) (n = 17 total; n = 14, COVID-19-naive, red circles; n = 3, COVID-19-experienced,
384 green circles) and 90 days post-boosting (G) (n = 11 total; n = 10 COVID-19-naive, red circles;
385 n = 1, COVID-19-experienced). LOD indicates limit of detection. Dotted black line represents
386 the presumptive protective titer as described²⁶. Numbers immediately above the x axis indicate
387 the number and percentage of patients with GMTs above 50 at each time point. Numbers above
388 graphed data represent the geometric mean titer (GMT) for each time point. Kruskal-Wallis with

389 Dunn's post-test; Only significant differences are shown: *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$;
390 ****, $P < 0.0001$).

391

392 SUPPLEMENTAL FIGURE LEGENDS

393 **Figure S1. Systems serology signature of COVID-19-naive and COVID-19-**
394 **experienced PAD patients compared to HD, Related to Figure 2.** Composite polar plots
395 depicting the mean level of -SARS-CoV-2-specific antibody features: (A) anti-Wuhan-1 spike,
396 S1, S2 and RBD (B) and anti-B.1.351 or B.1.617.2 spike antibodies in HD ($n = 20$), COVID-19-
397 naive PAD patients ($n = 18$) and COVID-19-experienced PAD patients ($n = 9$) 14 days following
398 the completion of mRNA vaccine series. The size of the wedge indicates the magnitude of the
399 mean value. The colors represent specific immunoglobulin subclass or class: IgG1, IgG2, IgG3,
400 IgA and IgM, or specific Fc γ R binding: Fc γ R2A, Fc γ R2B, Fc γ R3A or Fc γ R3B.

401 **Figure S2. Most tested immunoglobulin replacement products have low levels of**
402 **neutralizing activity, Related to Figure 3.** The relative infection rate of Vero-TMPRSS2 cells
403 following pre-incubation of 10^2 FFU of WA1/2020 (A) or B.1.617.2 (B) with serially-diluted
404 immunoglobulin replacement products starting at 500 μ g/ml.

405 **Figure S3. Immune response to primary Ad26.COVS vaccination and a SARS-**
406 **CoV-2 mRNA boosting.** Anti-Wuhan-1 spike (A) and RBD (B) endpoint titers in COVID-19-
407 naive PAD patients ($n = 3$; red circles) before, or 28, 60, 90, and 150 days after one dose of
408 Ad26.COVS vaccine and 14 and 90 days post mRNA booster. Serum neutralizing activity
409 against WA1/2020 (C) or B.1.617.2 (Delta) (D) in COVID-19-naive ($n = 3$, red circles) patients
410 before and 28 or 90 days following Ad26.COVS vaccination and 14 or 90 days after mRNA
411 booster. LOD indicates limit of detection. Solid blue line represents the upper limit of 95% CI of

412 unvaccinated HD anti-spike (**A**) or anti-RBD (**B**) end point titer pre-vaccination. Dotted black
413 line (**C-D**) represents the presumptive protective titer as described²⁶. Numbers above graphed
414 data (**A-D**) represent the geometric mean titer (GMT) for each time point. Bars (**A-B**) indicate
415 mean values.
416

417 **Table 1. Patients characteristics**

Patient number	Sex	Diagnosis	Immunoglobulin replacement product	Vaccine	COVID-19 infection to 1st vaccine (days)	Vaccine completion to booster (days)	Booster
1	F	CVID	GAMMAGARD	Pfizer	--	152	Pfizer
2	F	CVID	HIZENTRA	Pfizer	--	117	Pfizer
3	F	CVID	GAMMAGARD	Pfizer	--	--	--
4	F	CVID	Gammaplex	Pfizer	--	150	Pfizer
5	M	CVID	GAMMAGARD	Pfizer	--	143	Pfizer
6	F	CVID	GAMUNEX-C	Pfizer	--	--	--
7	F	SAB	none	Pfizer	96	134	Pfizer
8	F	CVID	HIZENTRA	Pfizer	--	128	Pfizer
9	F	SAB	HyQvia	J&J	--	162	Pfizer
10	F	CVID	GAMMAGARD	Pfizer	--	138	Pfizer
11	F	CVID	HIZENTRA	Pfizer	--	163	Pfizer
12	M	CVID	GAMUNEX-C	Moderna	--	150	Moderna
14	F	SAB	XEMBIFY	Pfizer	90	--	--
15	F	CVID	GAMUNEX-C	Moderna	181	--	--
16	F	SAB	none	J&J	--	--	--
17	F	CVID	GAMUNEX-C	Moderna	--	--	--
18	F	CVID	Cuvitru	Moderna	--	--	--
19	F	Hypogam	OCTAGAM	Pfizer	276	154	Pfizer
20	F	CVID	Gamunex-C	Moderna	--	--	--
21	F	SAB	Cuvitru	Pfizer	--	185	Pfizer
22	F	CVID	GAMUNEX-C	Pfizer	117	--	--
23	F	Hypogam	Xembify	Pfizer	--	108	Pfizer
24	F	CVID	PRIVIGEN	Moderna	222	--	--
25	F	Hypogam	None	Moderna	106	108	--
26	M	CVID	GAMUNEX-C	J&J	--	65	Pfizer
27	F	CVID	GAMMAGARD	Pfizer	--	--	--
28	F	Hypogam	GAMUNEX-C	Pfizer	--	158	Pfizer
29	F	CVID	HIZENTRA	Pfizer	--	104	Pfizer
30	F	SAB	GAMUNEX-C	Moderna	144	104	Moderna
31	F	CVID	GAMUNEX-C	Pfizer	36	--	--
Mean (days)					130	135	

418 F, female; M, male. CVID, common variable immune deficiency; Hypogam,
419 Hypogammaglobulinemia; SAB, specific antibody deficiency disorder.
420
421

422 **METHODS**

423 **Patients and samples.** The study was approved by the Institutional Review Board of
424 Washington University School of Medicine (Approval # 202104138). Patients were identified by
425 a medical record search for PAD, and their records were reviewed to confirm their diagnosis and
426 verify they met the inclusion criteria. COVID-19 vaccination status was reviewed, and subjects
427 were contacted if they were within the vaccination window or not yet immunized. Laboratory
428 values (**Table S2-S3**) were acquired based on review of patient history and records and were not
429 performed as part of this study. Reference values and ranges of specific tests are based on data
430 obtained at the time of original sampling from patient records.

431 Inclusion criteria included males and females over 18 years of age, health care provider-
432 documented PAD syndrome including common variable immunodeficiency (CVID), specific
433 antibody deficiency, or hypogammaglobulinemia, and the ability to give informed consent. Entry
434 criteria also included receipt of a SARS-CoV-2 vaccine within 14 days of enrollment, receipt of
435 the second dose of mRNA vaccine (Moderna mRNA-1273 or Pfizer BNT162b2) within 28 days
436 of the first visit, or receipt of one dose of adenoviral-vector vaccine (J&J Ad26.COV2.S) within
437 35 days of initial visit. Exclusion criteria included participation in an investigational study of
438 SARS-CoV-2 vaccines within the past year, history of HIV infection, an active cancer diagnosis,
439 treatment with immunosuppressive medications, history of hematologic malignancy, treatment
440 with anti-CD20 monoclonal antibody, receipt of live-attenuated vaccine within 30 days or any
441 inactivated vaccine within 14 days of SARS-CoV-2 vaccination, blood or blood product
442 donation within 30 days prior to study vaccination, and planned blood donation at any time
443 during or 30 days after the duration of subject study participation.

444 469 charts were reviewed, and 160 subjects were contacted. A total of 30 adults (27
445 females, 3 males) with PAD met eligibility requirements and agreed to enroll in the study (see
446 **Table 1**); we note a sex-bias in the enrollees from our PAD cohort, which is not typical for the
447 disease itself. Ages ranged from 20 to 82, with an average age of 48.4 years old. Twenty PAD
448 patients had CVID, six had specific antibody deficiency, and four had hypogammaglobulinemia.
449 Twenty-seven of these subjects had received immunoglobulin replacement therapy before and
450 during the study period from 9 different products. Nineteen subjects received the BNT162b2, 8
451 received mRNA-1273, and three received Ad26.COVS vaccines. Of the 30 subjects, 9 were
452 diagnosed with a prior SARS-CoV-2 infection with a positive nasal swab RT-PCR test, and one
453 received treatment with an anti-SARS-CoV-2 monoclonal antibody (bamlanivimab) 90 days
454 prior to study enrollment.

455 All subjects had one mandatory post-vaccine blood sample collection with optional pre-
456 vaccine and follow-up visits at days 60, 90, and 150 (± 14 days) after vaccination. The optional
457 pre-vaccination blood sample was collected up to 14 days before receiving vaccine. For subjects
458 who received a two-dose series of mRNA vaccines, the first post-vaccination blood collection
459 occurred 7 – 28 days after the second dose. For subjects receiving the Ad26.COVS single-dose
460 vaccine, the first post-vaccination blood sample was collected 21-35 days after immunization.
461 Since the study was non-interventional, patients were informed if they mounted an immune
462 response to the vaccine, but the decision to receive a booster was made between the patient and
463 their physician. Subjects who opted for boosting provided a blood sample up to 14 days prior to
464 receiving the booster dose, unless the subject previously provided a sample within 2 weeks as
465 part of the optional post-vaccine assessments. Subjects returned for an additional sample 7-28
466 days after receiving the booster (range 7-27 days, median 17 days, mean 17 days. One patient

467 had her post-booster sample drawn at day 35), with a second post-booster visit and sample
468 collection at 90 ± 14 days. Immunoglobulin replacement product vials that were used in PAD
469 patients were collected at each study visit and/or post-infusion at the Washington University
470 Allergy and Immunology Division infusion centers.

471 **Healthy donor controls.** Immunocompetent healthy donor volunteer blood samples were
472 obtained as previously described⁴¹.

473 **SARS-CoV-2 spike and RBD protein expression.** Genes encoding SARS-CoV-2 spike
474 protein (residues 1-1213, GenBank: MN908947.3) and RBD (residues 319-514) were cloned into
475 a pCAGGS mammalian expression vector with a C-terminal hexahistidine tag. The spike protein
476 was stabilized in a prefusion form using six proline substitutions (F817P, A892P, A899P,
477 A942P, K986P, V987P)⁴², and expression was optimized with a disrupted S1/S2 furin cleavage
478 site and a C-terminal foldon trimerization motif (YIPEAPRDGQAYVRKDGEWVLLSTFL)⁴³.
479 Expi293F cells were transiently transfected, and proteins were purified by cobalt-affinity
480 chromatography (G-Biosciences) as previously described^{44,45}.

481 **ELISA.** Maxisorp ELISA (Thermo Fisher) plates were coated with SARS-CoV-2
482 Whuan-1 spike or RBD (2 μ g/ml) overnight in sodium bicarbonate buffer, pH 9.3. Plates were
483 washed four times with PBS and 0.05% Tween-20 and blocked with 4% BSA in PBS for 1 h at
484 25°C. Plates were then incubated with 50 μ L of patient and healthy donor serially-diluted
485 samples (starting at 1/50) in 2% BSA PBS, for 2 hours at 25°C on a shaker. Immunoglobulin
486 replacement products were diluted to 10 mg/ml (average patient IgG level) and then treated as
487 described above. Plates were washed with PBS and 0.05% Tween-20 and incubated with
488 horseradish peroxidase (HRP)-conjugated goat anti-human IgG (H + L) (1:2000 dilution, Jackson
489 ImmunoResearch) for 1 h at room temperature. After washing, plates were developed with 100

490 μL of 3,3'-5,5' tetramethylbenzidine substrate (Thermo Fisher) for 120 sec and fixed with 50 μL
491 of 2N H_2SO_4 . Plates were read at 450 nM using a microplate reader (Synergy H1; BioTek).

492 **Luminex profiling.** Serum samples were analyzed by a customized Luminex assay to
493 quantify the levels of antigen-specific antibody subclasses and $\text{Fc}\gamma\text{R}$ binding profiles, as
494 previously described^{46,47}. Briefly, SARS-CoV-2 antigens were coupled to magnetic Luminex
495 beads (Luminex Corp) by carbodiimide-NHS ester-coupling (Thermo Fisher). Antigen-coupled
496 microspheres were washed and incubated with plasma samples at an appropriate sample dilution
497 (1:100 for antibody isotyping and 1:1000 for all low-affinity $\text{Fc}\gamma\text{Rs}$) overnight in 384-well plates
498 (Greiner Bio-One). Unbound antibodies were washed away, and antigen-bound antibodies were
499 detected by using a PE-coupled detection antibody for each subclass and isotype (IgG1, IgG2,
500 IgG3, IgA1, and IgM; Southern Biotech), and $\text{Fc}\gamma\text{Rs}$ were fluorescently labeled with PE before
501 addition to immune complexes ($\text{Fc}\gamma\text{R}2\text{a}$, $\text{Fc}\gamma\text{R}2\text{b}$, $\text{Fc}\gamma\text{R}3\text{a}$, $\text{Fc}\gamma\text{R}2\text{b}$; Duke Protein Production
502 facility). After one hour of incubation, plates were washed, and flow cytometry was performed
503 with an iQue (Intellicyt), and analysis was performed on IntelliCyt ForeCyt (v8.1). PE median
504 fluorescent intensity (MFI) is reported as a readout for antigen-specific antibody titers.

505 **Focus reduction neutralization test.** Serial dilutions of immunoglobulins products or
506 sera were incubated with 10^2 focus-forming units (FFU) of different strains of SARS-CoV-2 for
507 1 h at 37°C . Antibody-virus complexes were added to Vero-TMPRSS2 cell monolayers in 96-
508 well plates and incubated at 37°C for 1 h. Subsequently, cells were overlaid with 1% (w/v)
509 methylcellulose in MEM supplemented with 2% FBS. Plates were harvested 30 h later by
510 removing overlays and fixed with 4% PFA in PBS for 20 min at room temperature. Plates were
511 washed and sequentially incubated with an oligoclonal pool of SARS2-2, SARS2-11, SARS2-16,
512 SARS2-31, SARS2-38, SARS2-57, and SARS2-71^{48,49} anti-spike antibodies and HRP-

513 conjugated goat anti-mouse IgG (Sigma) in PBS supplemented with 0.1% saponin and 0.1%
514 BSA. SARS-CoV-2-infected cell foci were visualized using TrueBlue peroxidase substrate
515 (KPL) and quantitated on an ImmunoSpot microanalyzer (Cellular Technologies).

516 **Quantification and statistical analysis.** Statistical significance was assigned using
517 Prism Version 9 (GraphPad) when $P < 0.05$. Statistical analysis was determined by one-way
518 ANOVA with Dunnett's post-test, two-way ANOVA with Tukey post-test or a Kruskal-Wallis
519 with Dunn's post-test. The statistical tests, number of independent experiments, and number of
520 experimental replicates are indicated in the Figure legends.

521

522 **DATA AVAILABILITY**

523 All data reported in this paper will be shared upon request. Any additional information
524 required to reanalyze the data reported in this paper is available from the lead contact upon
525 request.

526


527 **REFERENCES**











- 528 1. Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON):
529 Common Variable Immunodeficiency Disorders. *J Allergy Clin Immunol Pract.*
530 2016;4(1):38-59.
- 531 2. Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological
532 Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors
533 of Immunity. *J Clin Immunol.* 2018;38(1):96-128.
- 534 3. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality
535 in common variable immune deficiency over 4 decades. *Blood.* 2012;119(7):1650-1657.
- 536 4. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and
537 common variable immunodeficiency (CVID). *Clin Exp Immunol.* 2000;120(2):225-231.
- 538 5. Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical
539 manifestations and complications. *Q J Med.* 1993;86(1):31-42.
- 540 6. Gathmann B, Mahlaoui N, Ceredih, et al. Clinical picture and treatment of 2212 patients
541 with common variable immunodeficiency. *J Allergy Clin Immunol.* 2014;134(1):116-126.
- 542 7. Bogaert DJ, Dullaers M, Lambrecht BN, Vermaelen KY, De Baere E, Haerynck F. Genes
543 associated with common variable immunodeficiency: one diagnosis to rule them all? *J*
544 *Med Genet.* 2016;53(9):575-590.
- 545 8. Maffucci P, Filion CA, Boisson B, et al. Genetic Diagnosis Using Whole Exome
546 Sequencing in Common Variable Immunodeficiency. *Front Immunol.* 2016;7:220.
- 547 9. de Valles-Ibanez G, Esteve-Sole A, Piquer M, et al. Evaluating the Genetics of Common
548 Variable Immunodeficiency: Monogenetic Model and Beyond. *Front Immunol.*
549 2018;9:636.
- 550 10. Tuijnenburg P, Lango Allen H, Burns SO, et al. Loss-of-function nuclear factor kappaB
551 subunit 1 (NFKB1) variants are the most common monogenic cause of common variable
552 immunodeficiency in Europeans. *J Allergy Clin Immunol.* 2018;142(4):1285-1296.
- 553 11. Abolhassani H, Hammarstrom L, Cunningham-Rundles C. Current genetic landscape in
554 common variable immune deficiency. *Blood.* 2020;135(9):656-667.
- 555 12. Ellis EF, Henney CS. Adverse reactions following administration of human gamma
556 globulin. *J Allergy.* 1969;43(1):45-54.
- 557 13. Friedli HR. Methodology and safety considerations in the production of an intravenous
558 immunoglobulin preparation. *Pharmacotherapy.* 1987;7(2):S36-40.
- 559 14. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in
560 the prevention of pneumonia in patients with common variable immunodeficiency. *J*
561 *Allergy Clin Immunol.* 2002;109(6):1001-1004.
- 562 15. Barahona Afonso AF, Joao CM. The Production Processes and Biological Effects of
563 Intravenous Immunoglobulin. *Biomolecules.* 2016;6(1):15.
- 564 16. Grifols. Plasma journey. <https://www.grifols.com/en/plasma-journey>. Accessed 01.24.22,
565 2022.
- 566 17. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human
567 disease: A review of evidence. *J Allergy Clin Immunol.* 2017;139(3S):S1-S46.
- 568 18. Hagin D, Freund T, Navon M, et al. Immunogenicity of Pfizer-BioNTech COVID-19
569 vaccine in patients with inborn errors of immunity. *J Allergy Clin Immunol.*
570 2021;148(3):739-749.

- 571 19. Arroyo-Sanchez D, Cabrera-Marante O, Laguna-Goya R, et al. Immunogenicity of Anti-
572 SARS-CoV-2 Vaccines in Common Variable Immunodeficiency. *J Clin Immunol*. 2021.
573 20. Salinas AF, Mortari EP, Terreri S, et al. SARS-CoV-2 Vaccine Induced Atypical Immune
574 Responses in Antibody Defects: Everybody Does their Best. *J Clin Immunol*.
575 2021;41(8):1709-1722.
576 21. Abo-Helo N, Muhammad E, Ghaben-Amara S, Panasoff J, Cohen S. Specific antibody
577 response of patients with common variable immunodeficiency to BNT162b2 coronavirus
578 disease 2019 vaccination. *Ann Allergy Asthma Immunol*. 2021;127(4):501-503.
579 22. Pulvirenti F, Fernandez Salinas A, Milito C, et al. B Cell Response Induced by SARS-
580 CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody
581 Deficiencies. *Cells*. 2021;10(11).
582 23. Bartsch YC, Wang C, Zohar T, et al. Humoral signatures of protective and pathological
583 SARS-CoV-2 infection in children. *Nat Med*. 2021;27(3):454-462.
584 24. Atyeo C, Fischinger S, Zohar T, et al. Distinct Early Serological Signatures Track with
585 SARS-CoV-2 Survival. *Immunity*. 2020;53(3):524-532 e524.
586 25. Ackerman ME, Barouch DH, Alter G. Systems serology for evaluation of HIV vaccine
587 trials. *Immunol Rev*. 2017;275(1):262-270.
588 26. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
589 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*.
590 2021;27(7):1205-1211.
591 27. Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 Variants and Vaccines. *N Engl*
592 *J Med*. 2021;385(2):179-186.
593 28. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes
594 Pfizer BNT162b2 neutralization. *Nature*. 2021.
595 29. Lu L, Mok BW, Chen LL, et al. Neutralization of SARS-CoV-2 Omicron variant by sera
596 from BNT162b2 or Coronavac vaccine recipients. *Clin Infect Dis*. 2021.
597 30. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2
598 Vaccine against Omicron Variant in South Africa. *N Engl J Med*. 2021.
599 31. VanBlargan L, Errico J, Halfmann P, et al. An infectious SARS-CoV-2 B.1.1.529
600 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med*.
601 2022.
602 32. Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron
603 Variant of SARS-CoV-2. *Nature*. 2021.
604 33. Dejnirattisai W, Zhou D, Ginn HM, et al. The antigenic anatomy of SARS-CoV-2
605 receptor binding domain. *Cell*. 2021;184(8):2183-2200 e2122.
606 34. CDC. COVID-19 Vaccines for Moderately or Severely Immunocompromised People.
607 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>.
608 Accessed 1.24.22, 2022.
609 35. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nat Rev*
610 *Mater*. 2021:1-17.
611 36. Alameh MG, Tombacz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of
612 mRNA and protein subunit vaccines by inducing robust T follicular helper cell and
613 humoral responses. *Immunity*. 2021;54(12):2877-2892 e2877.
614 37. Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estambouli H, Igyarto BZ. The mRNA-LNP
615 platform's lipid nanoparticle component used in preclinical vaccine studies is highly
616 inflammatory. *iScience*. 2021;24(12):103479.

- 617 38. Romero C, Diez JM, Gajardo R. Anti-SARS-CoV-2 antibodies in healthy donor plasma
618 pools and IVIG products-an update. *Lancet Infect Dis.* 2022;22(1):19.
- 619 39. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2
620 neutralizing antibodies. *Nature.* 2021.
- 621 40. Dejnirattisai W, Huo J, Zhou D, et al. Omicron-B.1.1.529 leads to widespread escape
622 from neutralizing antibody responses. *bioRxiv.* 2021.
- 623 41. Turner JS, O'Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce
624 persistent human germinal centre responses. *Nature.* 2021;596(7870):109-113.
- 625 42. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-
626 stabilized SARS-CoV-2 spikes. *Science.* 2020;369(6510):1501-1505.
- 627 43. Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG. Structure of bacteriophage T4
628 fibrinin: a segmented coiled coil and the role of the C-terminal domain. *Structure.*
629 1997;5(6):789-798.
- 630 44. Alsoussi WB, Turner JS, Case JB, et al. A Potently Neutralizing Antibody Protects Mice
631 against SARS-CoV-2 Infection. *J Immunol.* 2020;205(4):915-922.
- 632 45. Hassan AO, Case JB, Winkler ES, et al. A SARS-CoV-2 Infection Model in Mice
633 Demonstrates Protection by Neutralizing Antibodies. *Cell.* 2020;182(3):744-753 e744.
- 634 46. Brown EP, Dowell KG, Boesch AW, et al. Multiplexed Fc array for evaluation of
635 antigen-specific antibody effector profiles. *J Immunol Methods.* 2017;443:33-44.
- 636 47. Brown EP, Licht AF, Dugast AS, et al. High-throughput, multiplexed IgG subclassing of
637 antigen-specific antibodies from clinical samples. *J Immunol Methods.* 2012;386(1-
638 2):117-123.
- 639 48. Liu Z, VanBlargan LA, Bloyet LM, et al. Identification of SARS-CoV-2 spike mutations
640 that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe.*
641 2021;29(3):477-488 e474.
- 642 49. VanBlargan LA, Adams LJ, Liu Z, et al. A potently neutralizing SARS-CoV-2 antibody
643 inhibits variants of concern by utilizing unique binding residues in a highly conserved
644 epitope. *Immunity.* 2021;54(10):2399-2416 e2396.
- 645

646





● HD ● COVID-19-naive PAD ● COVID-19-experienced PAD

